Jim Simons
CLYM icon

Jim Simons’s Climb Bio CLYM Stock Holding History

Jim Simons’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Sell
192,700
-24,600
-11% -$254K ﹤0.01% 1834
2026
Q1 		$1.49M Sell
217,300
-103,300
-32% -$596K ﹤0.01% 2051
2025
Q4 		$1.28M Sell
320,600
-216,500
-40% -$520K ﹤0.01% 2137
2025
Q3 		$1.08M Buy
537,100
+41,600
+8% +$77.2K ﹤0.01% 2447
2025
Q2 		$614K Sell
495,500
-18,898
-4% -$23.5K ﹤0.01% 2732
2025
Q1 		$628K Buy
514,398
+142,098
+38% +$230K ﹤0.01% 2644
2024
Q4 		$670K Buy
372,300
+303,700
+443% +$1.1M ﹤0.01% 2702
2024
Q3 		$349K Buy
68,600
+31,600
+85% +$224K ﹤0.01% 2922
2024
Q2 		$263K Buy
37,000
+26,383
+248% +$176K ﹤0.01% 2960
2024
Q1 		$29K Buy
10,617
+14
+0.1% +$39 ﹤0.01% 3562
2023
Q4 		$29K Buy
+10,603
New +$27.6K ﹤0.01% 3538

Other funds holding CLYM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Braidwell
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jim Simons's CLYM Position: Q2 2026 in Review

Jim Simons reduced its Climb Bio (CLYM) stake by 11% in Q2 2026, selling an estimated $254K and leaving 192,700 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Jim Simons first reported a position in CLYM in Q4 2023 and has held it in 11 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Jim Simons held 192,700 shares of Climb Bio worth $2.51M as of Q2 2026.
  • Jim Simons sold 24,600 Climb Bio shares in Q2 2026, an estimated $254K.
  • Climb Bio made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #1834 holding.
  • Jim Simons first reported a position in Climb Bio in Q4 2023 and has held it in 11 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.